Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

Cardiovascular disease in diabetes and CKD  residual risk The promise of epigenetics
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands
  • Overview

    Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.

  • Educational information

    This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.

  • Faculty

    Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free